Luminex and Abbott Sign Agreement for Global Distribution of the xTAG™ Respiratory Viral Panel
Complete the form below to unlock access to ALL audio articles.
Luminex Molecular Diagnostics has signed a global sales and distribution agreement with Abbott’s molecular diagnostics business. Under the terms of the agreement, Abbott will have exclusive rights to distribute Luminex’s new xTAG™ Respiratory Viral Panel (RVP) worldwide outside the United States and semi-exclusive rights in the United States.
Based on Luminex’s xMAP® multiplexing technology, xTAG RVP was created by Luminex Molecular Diagnostics, in partnership with a team of leading virologists and infectious disease specialists. In a matter of hours from a single patient sample, the test allows doctors to detect the presence or absence of several viruses and subtypes at once.
“We believe that xTAG RVP has the potential to significantly impact the detection, treatment, and control of respiratory viruses worldwide,” said Douglas Bryant, executive vice president and chief operating officer of Luminex.
“Abbott’s long-standing dedication to improve the quality of human health, combined with their global customer base, will make them a strong partner in bringing xTAG RVP to more physicians, public health authorities and patients around the world.”
xTAG RVP received 510(k) clearance by the U.S. Food and Drug Administration in January 2008, and became CE marked for sale in Europe in November 2006.
